{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T11:10:09Z","timestamp":1683285009410},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,15]]},"DOI":"10.2146\/ajhp160980","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T01:35:12Z","timestamp":1516239312000},"page":"177-182","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of gastrointestinal bleeding with idarucizumab in a patient receiving dabigatran"],"prefix":"10.1093","volume":"75","author":[{"given":"Jennifer","family":"Mourafetis","sequence":"first","affiliation":[{"name":"Memorial Regional Hospital, Hollywood, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Norman","family":"Doctor","sequence":"additional","affiliation":[{"name":"Memorial Regional Hospital, Hollywood, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Leung","sequence":"additional","affiliation":[{"name":"Memorial Regional Hospital, Hollywood, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041105241573800_b1-0750177","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t2019041105241573800_b2-0750177","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1161\/CIRCULATIONAHA.111.031146","article-title":"Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism","volume":"125","author":"Granger","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b3-0750177","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b4-0750177","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.drudis.2014.05.013","article-title":"Reversal of target-specific oral anticoagulants","volume":"19","author":"Siegal","year":"2014","journal-title":"Drug Discov Today"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041105241573800_b5-0750177","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.2146\/ajhp130041","article-title":"Pharmacologic interventions for reversing the effects of oral anticoagulants","volume":"70","author":"Kalus","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041105241573800_b6-0750177","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2146\/ajhp130243","article-title":"Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations","volume":"70","author":"Nutescu","year":"2013","journal-title":"Am J Health-Syst Pharm"},{"key":"key\n\t\t\t\t2019041105241573800_b7-0750177","volume-title":"Praxbind (idarucizumab) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041105241573800_b8-0750177","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal\u2014full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105241573800_b9-0750177","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041105241573800_b10-0750177","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b11-0750177","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t2019041105241573800_b12-0750177","volume-title":"Pradaxa (dabigatran etexilate mesylate) package insert","year":"2015"},{"key":"key\n\t\t\t\t2019041105241573800_b13-0750177","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.05.006","article-title":"Systemic thrombolysis for ischemic stroke after antagonizing dabigatran with idarucizumab\u2014a case report","volume":"25","author":"Sch\u00e4fer","year":"2016","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key\n\t\t\t\t2019041105241573800_b14-0750177","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1002\/phar.1830","article-title":"Management of dabigatran-associated bleeding with two doses of idarucizumab plus hemodialysis","volume":"36","author":"Marino","year":"2016","journal-title":"Pharmacotherapy"},{"key":"key\n\t\t\t\t2019041105241573800_b15-0750177","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bcpt.12696","article-title":"Idarucizumab for reversal of dabigatran prior to acute surgery: a schematic approach based on a case report","volume":"120","author":"Rosenberg","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"key\n\t\t\t\t2019041105241573800_b16-0750177","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/15563650.2016.1187737","article-title":"Idarucizumab for dabigatran overdose","volume":"54","author":"Peetermans","year":"2016","journal-title":"Clin Toxicol"},{"key":"key\n\t\t\t\t2019041105241573800_b17-0750177","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041105241573800_b18-0750177","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","author":"Lip","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105241573800_b19-0750177","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105241573800_b20-0750177","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","author":"Graham","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b21-0750177","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105241573800_b22-0750177","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105241573800_b23-0750177","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105241573800_b24-0750177","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1016\/j.jacc.2014.03.021","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105241573800_b25-0750177","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t2019041105241573800_b26-0750177","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105241573800_b27-0750177","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105241573800_b28-0750177","first-page":"1467","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"17","author":"Heidbuchel","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105241573800_b29-0750177","first-page":"1","article-title":"2015 ACC\/AHA\/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction","volume":"135","author":"Levine","year":"2017","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b30-0750177","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCINTERVENTIONS.113.001150","article-title":"Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions","volume":"7","author":"Capodanno","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"key":"key\n\t\t\t\t2019041105241573800_b31-0750177","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","article-title":"Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis","volume":"379","author":"Palmerini","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105241573800_b32-0750177","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.jacc.2014.06.1193","article-title":"Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review","volume":"64","author":"Dewilde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105241573800_b33-0750177","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/eurheartj\/ehs408","article-title":"Acute management of bleeding patients on novel oral anticoagulants","volume":"34","author":"Siegal","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t2019041105241573800_b34-0750177","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1053\/j.ajkd.2012.08.047","article-title":"Removal of dabigatran by hemodialysis","volume":"61","author":"Chang","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t2019041105241573800_b35-0750177","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2017.09.1085","article-title":"2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants","author":"Tomaselli","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t2019041105241573800_b36-0750177","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019041105241573800_b37-0750177","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab: the antidote for reversal of dabigatran","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t2019041105241573800_b38-0750177","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t2019041105241573800_b39-0750177","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041105241573800_b40-0750177","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041105241573800_b41-0750177","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bcp.12366","article-title":"Coagulation assays and plasma fibrinogen concentrations in real-world patients with atrial fibrillation treated with dabigatran","volume":"78","author":"Chin","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t2019041105241573800_b42-0750177","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1160\/TH13-04-0301","article-title":"The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples","volume":"110","author":"Hapgood","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/75\/4\/177\/28346989\/ajhp0177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T13:36:06Z","timestamp":1570628166000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/75\/4\/177\/5101902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp160980","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2,15]]},"published":{"date-parts":[[2018,2,15]]}}}